Clinical Trial Update: TG4010 and Nivolumab in Patients With Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update reporting completion of a study evaluating TG4010 in combination with nivolumab for non-small cell lung cancer, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TG4010 (MVA-MUC1-IL-2 therapeutic cancer vaccine)
• nivolumab (nivolumab)

Snippet

Sponsor: Megan Daly, MD | Conditions: Recurrent Non-Small Cell Lung Carcinoma, Stage I Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2025-11-10